论文部分内容阅读
克里唑替尼(crizotinib,1),化学名为3-[(1R)-1-(2,6-二氯-3-氟苯基)乙氧基]-5-[1-(4-哌啶基)-1H-吡唑-4-基]-2-氨基吡啶,是由辉瑞公司研发的用于治疗间变性淋巴瘤激酶(ALK)阳性的局部晚期或转移性的非小细胞肺癌(NSCLC)的小分子激酶抑制剂,是目前唯一一个治疗该类疾病的药物,2011年8月获FDA批准在美国上市,随后在韩国、日本、欧盟上市,2013年1月获
Crizotinib (1), chemically named 3 - [(1R) -1- (2,6-dichloro-3-fluorophenyl) ethoxy] -5- [1- Piperidinyl) -1H-pyrazol-4-yl] -2-aminopyridine is a locally advanced or metastatic non-small cell lung carcinoma (RK) developed by Pfizer for the treatment of anaplastic lymphoma kinase (ALK) NSCLC) small molecule kinase inhibitor, is currently the only drug for the treatment of such diseases, FDA approved in August 2011 in the United States, followed by South Korea, Japan, the EU market, January 2013